MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-29-2024
PetIQ Retained Earnings 2011-2026 | PETQ
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -161 M | -163 M | -115 M | -93.4 M | -15.9 M | -4.45 M | -3.49 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.49 M | -163 M | -79.3 M |
Quarterly Retained Earnings PetIQ
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -143 M | - | -156 M | -107 M | -111 M | -115 M | -100 M | -92.5 M | -96.5 M | -98.6 M | -98.6 M | -98.6 M | -98.6 M | -15.9 M | -15.9 M | -15.9 M | -15.9 M | -4.45 M | -4.45 M | -4.45 M | -4.45 M | -3.49 M | -3.49 M | -3.49 M | -3.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.49 M | -156 M | -58.8 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Cronos Group
CRON
|
1.06 B | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
-661 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
-157 M | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
Perrigo Company plc
PRGO
|
-3.68 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 7.33 | -0.48 % | $ 4.53 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |